Welcure Drugs & Pharmaceuticals Share Price
0.24+0.01 (+4.35%)
-71.37% past 1 Year
Welcure Drugs & Pharmaceuticals Ltd is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets capsules and dry syrups. The Company is manufacturing
Corporate filings & documents
Announcements
Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Ltd held on today i.e. Tuesday 14th July 2026.
1 month agoOutcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Ltd held on today i.e. Tuesday 14th July 2026.
1 month agoResignation of Company Secretary and Compliance Officer
2 months agoResignation of Company Secretary and Compliance Officer
2 months agoOutcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Friday 19th June 2026
2 months agoOutcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Friday 19th June 2026
2 months agoNewspaper Clipping of Audited Financials Results for the 4th Quarter and Annual year ended 31st March 2026.
3 months agoNewspaper Clipping of Audited Financials Results for the 4th Quarter and Annual year ended 31st March 2026.
3 months agoSubmission of Annual Secretarial Compliance Report for the year ended 31st March. 2026.
3 months agoSubmission of Annual Secretarial Compliance Report for the year ended 31st March. 2026.
3 months agoAudited Standalone Financial Results for the Quarter and Year Ended 31st March 2026
3 months agoAudited Standalone Financial Results for the Quarter and Year Ended 31st March 2026
3 months agoOutcome of the Meeting of Board of Directors of the Company held on today i.e. Friday 29th May 2026
3 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve Audited Financial Results for the quarter/year ended 31st March 2026 along with Statement of Assets and Liabilities and Cash Flow Statement for the year ended 31st March 2026.
3 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve Audited Financial Results for the quarter/year ended 31st March 2026 along with Statement of Assets and Liabilities and Cash Flow Statement for the year ended 31st March 2026.
3 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Welcure Drugs & Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L68100DL1996PLC227773</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Palak Jain <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Chintan Didawala Ganpat <br/> Designation: Managing Director and CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 23/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Welcure Drugs & Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L68100DL1996PLC227773</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Palak Jain <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Chintan Didawala Ganpat <br/> Designation: Managing Director and CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 23/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoCertificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations 2018 for the 4th Quarter and Annual year ended 31st MArch 2026.
5 months agoIntimation of Closure of Trading Window for the 4th Quarter and Annual Year Ended 31 March 2026
5 months agoIntimation of Closure of Trading Window for the 4th Quarter and Annual Year Ended 31 March 2026
5 months agoNewspaper Clipping of Unaudited Financials for 3rd Quarter ended December 21 2025.
6 months agoNewspaper Clipping of Unaudited Financials for 3rd Quarter ended December 21 2025.
6 months agoUnaudited Financials Results for the 3rd Quarter ended on 31st December 2025
6 months agoOutcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Thursday 12th February 2026
6 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve Un-audited Financial Results for the quarter & Nine month ended December 31 2025 along with Limited review report (Financial Results).
6 months agoCertificate under Regulation 74 (5) of SEBI (DP) Regulations 2018 for the 3rd Quarter ended 31st December 2025.
8 months agoIntimation of Closure of Trading Window
8 months agoOutcome of the Meeting of the Board of Directors of Welcure Drugs and PharmaceuticalsLimited held today i.e. Saturday December 06 2025
9 months agoPostponment of the meeting of the Right Issue Committe of the Welcure Drugs and Pharmaceuticals Limited which was to be held today i.e Monday December 05 2025
9 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/12/2025 inter alia to consider and approve various matters in connection with the Rights Issue
9 months agoResignation of Independent Director of the Company
9 months agoOutcome of the Meeting of the Board of Directors of Welcure Drugs And PharmaceuticalsLimited held today i.e. Monday December 01 2025
9 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/12/2025 inter alia to consider and approve To augment the financial resources of the Company via funds raising by way of issue of equityshares/convertible instruments/other securities through preferential allotment right issue QIPs ADR GDR FCCB or any other method or combination thereof in one or more trenches
9 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/11/2025 inter alia to consider and approve Intimation of Board Meeting to be held on Thursday November 27 2025.
9 months agoNewspaper Clipping of Unaudited Financial Results for Quarter and Half Year ended September 30 2025.
9 months agoResults-Unaudited Financial Statements For The Quarter And Half Year Ended 30th September 2025.
9 months agoOutcome of the meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e Thursday 13th November 2025.
9 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve the Un-audited Financial Results for thequarter and half year ended September 30 2025 along with Limited review report (FinancialResults).
10 months agoOutcome of the Board Meeting-Allotment of Bonus Shares
10 months agoCertificate Under Regulation 74(5) of SEBI ( Depository and Participants) Regulation 2018 for the 2nd Quarter Ended 30th September 2025.
10 months agoFixation of Record Date for Stock Split/Sub-Division of Shares & Bonus issue.
11 months agoOutcome of Board Meeting held on 07 October 2025 of Welcure Pharmaceuticlas Limited.
11 months agoVoting Results of 33rd Annual General Meeting of Welcure Pharmaceutical Limited held on 27th September 2025.
11 months agoOutcome of the Board Meeting
11 months agoProceedings of the AGM of the Company
11 months agoOutcome of the AGM of the company
11 months agoIntimation of Closure of Trading Window
11 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/09/2025 inter alia to consider and approve the meeting of the board of Directors of the Company which was to be held on 27th September 2025 has been postponed and is re-scheduled to be held on Saturday 27th September 2025.
11 months agoNewspaper Publication of Notice of AGM of the Company
12 months agoWelcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2025 inter alia to consider and approve To take on record and deliberate upon the Letter of Intent (LOI) received from TelexcellTrade PTE LTD Singapore for a proposed acquisition of up to 25% equity stake inWelcure Drugs & Pharmaceuticals Ltd. at an indicative price of Rs. 20 per share (a substantial premium over the prevailing market price).
1 year agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2025-10-16
Bonus
1:10
2025-10-16
Split
10:1
Company details
Registered office
Plot No. 55, Office No. 104 First Floor, Vijay Black Laxmi Nagar, East Delhi Delhi Delhi PIN: 110092 Tel No: NULL Fax No: NULL Email: [email protected] Internet: www.welcure.co.in
Registrars
D-153/A, 1st Floor,Okhla Industrial Area, Phase - I, New Delhi - 110020 D-153/A, 1st Floor Okhla Industrial Area Phase - I PIN: Tel No: 91-011-26812682/84 Fax No: 91-11-26292681 Email: [email protected]
Management
Yogeshkumar Prajapati, Non Executive Independent Director
Bhumika Pradhan, Non Executive Independent Director
Ravi Thakor, Non Executive Independent Director
Chintan Didawala, Managing Director
Details
BSE 524661
NSE NULL
ISIN INE331C01025